Construction method and application of escherichia coli engineering strain for improving yield of L-lysine by using ethylene glycol

By constructing an expression plasmid vector in E. coli, including genes encoding enzymes that promote the utilization of ethylene glycol and lysine synthesis pathway, the problems of low production efficiency of L-lysine and difficult isolation and purification in the prior art are solved, and efficient and low-cost production of L-lysine is achieved.

CN120158468APending Publication Date: 2025-06-17MINT BIOTECH LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202311722129.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-12-14
Publication Date
2025-06-17

AI Technical Summary

Technical Problem

In the prior art, the efficiency of synthesis of L-lysine using glucose is low and the difficulty of separation and purification is high, which limits its large-scale production and application.

Method used

The utilization of glycol and expression of lysine by the host cell is increased by constructing an expression plasmid vector or vector combination containing genes encoding enzymes that promote ethylene glycol utilization and lysine synthesis pathway enzymes, such as enzymes in the glycerol dehydrogenase gldA, lactaldehyde reductase fucO, and lysine biosynthesis pathway.

Benefits of technology

It has achieved the improvement of L-lysine expression and yield in E. coli, reduced production costs and energy consumption, and is environmentally friendly.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004607774770000031
    Figure BDA0004607774770000031
  • Figure BDA0004607774770000041
    Figure BDA0004607774770000041
  • Figure BDA0004607774770000081
    Figure BDA0004607774770000081
Patent Text Reader

Abstract

The invention relates to escherichia coli engineering bacteria co-utilizing glucose and ethylene glycol and a method for producing L-lysine through fermentation of the escherichia coli engineering bacteria, a genetic engineering method is adopted to obtain a genetic engineering strain, and the genetic engineering strain substantially expresses ethylene glycol metabolism genes including ethylene glycol dehydrogenase, acetaldehyde dehydrogenase and glycollic acid dehydrogenase; and aspartic acid aminotransferase, aspartic acid kinase, aspartic acid semialdehyde dehydrogenase, 4-hydroxytetrahydrobipicolinate synthase, meso-diaminopimelate dehydrogenase, 4-hydroxytetrahydropicolinic acid reductase, pimelate decarboxylase, phosphoenolpyruvate carboxylase, tetrahydropicolinate acetyltransferase, N-acetyl-L, L-dihydroxypicolinate, N-acetyl-L, L-dihydroxypicolinate, N-acetyl-L, L-dihydroxypicolinate, N-acetyl-L, L-dihydroxypicolinate and N-acetyl-L-dihydroxypicolinate. L-diamino pimelic acid amino transaminase and N-acetyl diamino pimelic acid deacetylase are added into the reaction system; the gene engineering strain is an E.coli BW25113 strain of which the genes of ldhA, pta, poxB, adhE, pflB, mgsA, frdA, cadA, ldcC, yqhD and ycdW are substantially inactivated. The genetic engineering strain is subjected to fermentation culture by taking glucose and ethylene glycol as carbon sources, and L-lysine is separated from a culture after the culture is finished.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biochemical engineering, and relates to a method for constructing an Escherichia coli engineering bacterium using ethylene glycol and its fermentation production of L-lysine. Background Art

[0002] Ethylene glycol has extensive industrial application value and can be used to manufacture polyester plastics, such as polyethylene terephthalate. As a common industrial fermentation substrate, glucose has a high degree of overlap between the processes of participating in biomass synthesis and synthesizing high-value chemicals during the metabolic conversion of microbial cell factories, which limits the efficiency of using glucose to synthesize target products. Ethylene glycol can minimize the interaction between the biomass and chemical synthesis pathways and improve the substrate utilization rate. In addition, ethylene glycol is relatively economical in price and can be obtained through the electrochemical conversion of CO2, hydrolysis of plastic waste, or hydrogenolysis of cellulose waste. Therefore, it is a potential abundant renewable substrate and can be used as an advantageous substrate for microorganisms to produce high-value chemicals.

[0003] L-lysine is the first essential amino acid in the human body and is an important component of synthesizing nucleoprotein, hemoglobin, and carnitine, an important carrier for fatty acid metabolism. It is also an important amino acid for promoting the regeneration of brain nerve cells. Lysine has positive nutritional significance in promoting human growth and development, enhancing the body's immunity, antiviral, promoting fat oxidation, and relieving anxiety. Currently, L-lysine mainly comes from chemical synthesis, but its large-scale production and application are limited by low synthesis efficiency and difficulty in separation and purification. Compared with chemical synthesis methods, microbial synthesis of L-lysine has the advantages of low cost, low energy consumption, high yield, strong selectivity, and environmental friendliness. In recent years, a large amount of research work has been invested in optimizing the L-lysine biosynthesis metabolic network and culture conditions. Escherichia coli has been widely used in the research and production of L-lysine biosynthesis due to its clear genetic background and fast growth rate. Summary of the Invention

[0004] In Escherichia coli, ethylene glycol can be converted into glyoxylate and then enter the metabolic network of Escherichia coli for utilization. It is found that three enzymes are required to catalyze the reaction of ethylene glycol to glyoxylate, namely lactaldehyde reductase, lactaldehyde dehydrogenase, and glycolate oxidase, and the encoding genes are fucO, aldA, and glcDEF respectively, which catalyze the sequential conversion of ethylene glycol into glycolaldehyde, glycolic acid, and finally into glyoxylate. The Fe 2+ -dependent propanediol oxidoreductase FucO is easily oxidized and inactivated, so it is sensitive to oxygen, and its mutant FucO I6L,L7V can improve the oxygen stability of FucO. In addition, the NAD-dependent glycerol dehydrogenase encoded by the gldA gene in Escherichia coli can catalyze glycerol to react to form dihydroxyacetone, and the GldA protein subunit requires Zn 2+Catalyze reactions as cofactors. At the same time, GldA also has a wide substrate specificity and can react with ethylene glycol as a substrate to produce glycolaldehyde. In addition, inactivating glycolaldehyde reductase YqhD and glyoxylate / hydroxypyruvate reductase YcdW can improve the conversion rate of ethylene glycol.

[0005] Specific aspects of the present invention are as follows:

[0006] The first aspect of the present invention provides an expression plasmid vector or a combination of expression plasmid vectors, and the vector or combination comprises: a first group of polynucleotides and a second group of polynucleotides, wherein the first group of polynucleotides comprises at least one polynucleotide encoding an enzyme that promotes the utilization of ethylene glycol; the second group of polynucleotides comprises at least one polynucleotide encoding an enzyme in the lysine synthesis pathway;

[0007] and a backbone plasmid that can replicate autonomously in a host cell.

[0008] In a specific embodiment of the present invention, the plasmid vector or the combination of vectors is used to promote the utilization of ethylene glycol by a host cell and / or enhance the expression level of lysine.

[0009] In a specific embodiment of the present invention, the first group of polynucleotides includes a) a gene encoding glycerol dehydrogenase gldA or a mutant thereof, or lactaldehyde reductase fucO or a mutant thereof; and / or b) a gene encoding lactaldehyde dehydrogenase (aldA) or a mutant thereof.

[0010] In a specific embodiment of the present invention, the glycerol dehydrogenase is a glycerol dehydrogenase or a propanediol / glycerol bifunctional dehydrogenase derived from the genus Escherichia, such as AAC43051 derived from Escherichia coli, or a glycerol dehydrogenase derived from Escherichia albertii such as OSL28309.1; or a glycerol dehydrogenase derived from Klebsiella pneumoniae such as ABR79620, or a glycerol dehydrogenase derived from the genus Shigella such as Shigella boydii or Shigella dysenteriae (such as ABB68416.1 or ABB63725.1), or a glycerol dehydrogenase derived from Streptococcal pneumoniae such as VTQ29411.1, or a glycerol dehydrogenase derived from Bacillus stearothermophilus such as AAA22477, or a glycerol dehydrogenase (alcohol / choline dehydrogenase) derived from Bacillus subtilis such as CAB15083.2, or a glycerol dehydrogenase derived from Pseudomonas putida such as AAC44426, or a glycerol dehydrogenase derived from Clostridium saccharobutylicum such as AAA83520.1, or a glycerol dehydrogenase derived from Clostridium acetobutylicum such as AAK79593.1, or a glycerol dehydrogenase derived from the genus Salmonella such as CNU06578.1, or an alcohol dehydrogenase (glycerol dehydrogenase) derived from Corynebacterium glutamicum such as SJM54452.1, and may also be a propanediol / glycerol bifunctional dehydrogenase MTU07760.1 derived from the genus Parasutterella excrementihominis, as well as natural or artificial mutants of enzymes derived from the same species. The glycerol dehydrogenase gldA is derived from Escherichia coli; or from Klebsiella pneumoniae.

[0011] Preferably, the glycerol dehydrogenase gldA derived from Escherichia coli has a protein sequence accession number of AAC43051 (ec.gldA); preferably, the glycerol dehydrogenase gldA derived from Klebsiella pneumoniae has a protein sequence accession number of ABR79620 (kp.gldA); or an enzyme having the above enzyme activity and having at least 96%, or 97%, or 98%, or at least 99% sequence identity with the amino acid sequence represented by the protein accession number AAC43051 or ABR79620.

[0012] In a specific embodiment of the present invention, the lactaldehyde reductase fucO is derived from Escherichia coli.

[0013] Preferably, the lactaldehyde reductase fucO has a protein sequence accession number of AAA23825, or an enzyme having the above enzyme activity and having at least 96%, or 97%, or 98%, or at least 99% sequence identity with the amino acid sequence represented by the protein accession number AAA23825. Preferably, it is the lactaldehyde reductase fucO mutant FucO I6L,L7V 。

[0014] In a specific embodiment of the present invention, the second group of polynucleotides comprises at least one gene of at least one enzyme in the following lysine biosynthetic pathway:

[0015] The lysine biosynthetic pathway of KEGG entry M00016;

[0016] The lysine biosynthetic pathway of KEGG entry M00525;

[0017] The lysine biosynthetic pathway of KEGG entry M00526;

[0018] The lysine biosynthetic pathway of KEGG entry M00527;

[0019] The lysine biosynthetic pathway of KEGG entry M00030;

[0020] The lysine biosynthetic pathway of KEGG entry M00433; and

[0021] The lysine biosynthetic pathway of KEGG entry M00031.

[0022] In a specific embodiment of the present invention, the second group of polynucleotides comprises one or more genes of the lysine biosynthetic pathway of KEGG entry M00016.

[0023] In a specific embodiment of the present invention, the second group of polynucleotides comprises one or more genes listed in Table 1:

[0024] Table 1 Enzymes Involved in the Lysine Biosynthesis Pathway

[0025]

[0026]

[0027] In a specific embodiment of the present invention, the second group of polynucleotides comprises a coding sequence of a homologous polypeptide of any one of the enzymes listed in Table 1 that is involved in lysine biosynthesis.

[0028] In a specific embodiment of the present invention, the second group of polynucleotides comprises one or more genes encoding the following enzymes: aspartate aminotransferase aspC, aspartate kinase lysC, aspartate semialdehyde dehydrogenase asd, 4-hydroxy-tetrahydrodipicolinate synthase dapA, meso-diaminopimelate dehydrogenase ddh, 4-hydroxy-tetrahydropyridinedicarboxylic acid reductase dapB, pimelate decarboxylase LysA, tetrahydropyridinemono-carboxylic acid acetyltransferase ykuQ, N-acetyl-L,L-diaminopimelate aminotransferase patA or N-acetyl-diaminopimelate deacetylase ykuR.

[0029] In a specific embodiment of the present invention, the vector or vector combination further comprises a third group of polynucleotides, and the third group of polynucleotides comprises at least one polynucleotide encoding an enzyme that promotes the accumulation of OAA; preferably phosphoenolpyruvate carboxylase ppc [EC:4.1.1.31].

[0030] In a specific embodiment of the present invention, the vector or vector combination further comprises a fourth group of polynucleotides, and the fourth group of polynucleotides comprises at least one polynucleotide encoding a polypeptide that aids in lysine synthesis, such as a tetracycline efflux pump polypeptide or a fragment thereof, see CN 106795209 A.

[0031] In a specific embodiment of the present invention, the vector or vector combination further comprises a fifth group of polynucleotides, and the fifth group of polynucleotides comprises at least one polynucleotide encoding a lysine derivative synthase; further, the lysine derivative is cadaverine, and the lysine derivative synthase is lysine decarboxylase.

[0032] In a specific embodiment of the present invention, the polynucleotides in the first to fifth groups of polynucleotides are homologous or heterologous to the host cell.

[0033] In a specific embodiment of the present invention, the polynucleotides in the first to fifth groups of polynucleotides comprise codon optimization for the host cell.

[0034] The nucleotide sequences, polynucleotides, and DNA molecules used in the present invention are not limited to functional regions and may include at least one of an expression inhibitory region, a coding region, a leader sequence, an exon, an intron, and an expression cassette. In addition, the nucleotide sequence or polynucleotide may include double-stranded DNA or single-stranded DNA (i.e., the sense strand and the antisense strand that make up double-stranded DNA) or RNA. A polynucleotide containing a specific polynucleotide sequence may include fragments and / or mutants of the specific polynucleotide sequence. A fragment of a polynucleotide refers to a part of the polynucleotide that encodes a polypeptide providing substantially the same function as the polypeptide encoded by the complete polynucleotide. Examples of mutants of a specific polynucleotide sequence include naturally occurring allelic mutants, artificial mutants, and polynucleotide sequences obtained by deleting, substituting, adding, and / or inserting one or more nucleotides in the specific polynucleotide sequence. It should be understood that such fragments and / or mutants of a specific polynucleotide sequence encode polypeptides having substantially the same function as the polypeptide encoded by the original specific polynucleotide sequence.

[0035] In a specific embodiment of the present invention, the polynucleotides in the first to fifth groups of polynucleotides are operably linked to a promoter, which is homologous or heterologous to the host cell.

[0036] On the other hand, the present invention relates to a transformant that contains one or more expression plasmid vectors or a combination thereof in a host cell.

[0037] In the present invention, a transformant is a host cell that has been altered by introducing one or more expression plasmid vectors into the host cell, wherein the one or more expression plasmid vectors are the same or different. In certain embodiments, the transformant is obtained by transforming and introducing the plasmid vector into a host cell that is competent for the expression plasmid vector.

[0038] Yet another aspect of the present invention provides a mutant host cell that contains a first group of polynucleotides and a second group of polynucleotides integrated into the chromosome of the host cell.

[0039] In a specific embodiment of the present invention, the mutant host cell further contains a third group of polynucleotides, a fourth group of polynucleotides, or a fifth group of polynucleotides.

[0040] In the present invention, the first to fifth polynucleotides can be integrated into the host cell chromosome according to methods such as plasmid transformation, phage-mediated transformation, and genome editing.

[0041] In a specific embodiment of the present invention, the expression of one or both of the following genes in the transformant or mutant host cell is inhibited, attenuated, or eliminated: glyoxylate / hydroxypyruvate reductase ycdW and / or NADPH-dependent aldehyde reductase yqhD.

[0042] In a further preferred embodiment of the present invention, the metabolic by - product production pathways of succinic acid, lactic acid, ethanol, acetic acid and formic acid and the lysine degradation pathway in the transformant or mutant are inhibited or blocked.

[0043] The present invention inhibits, reduces or eliminates the expression of the corresponding enzyme by gene knockout. Those skilled in the art know that other methods for inhibiting enzyme expression or reducing / eliminating enzyme functional activity can also be applied to the construction of genetically engineered strains, such as promoter knockout or replacement, introducing enzyme - inactivating / diminishing mutations, deleting (or partially deleting) essential functional elements or regions for gene transcription / translation, introducing mutations or nucleic acid sequences that accelerate the degradation of mRNA guiding enzyme synthesis, introducing mutations or protein tags that accelerate enzyme degradation / decomposition / inactivation, inhibiting signal activation, RNA interference and gene silencing, CRISPRi, etc.; in the specific embodiments of the present invention, the expression level of the enzyme is reduced by more than 30% or the activity of the enzyme is reduced by more than 30%.

[0044] In the specific embodiments of the present invention, the host strain of the transformant or mutant host cell is selected from bacteria or fungi; optionally, the host strain is selected from wild or genetically engineered Escherichia coli, Bacillus, Corynebacterium, yeast or Streptomyces; optionally, the host strain is selected from wild or genetically engineered Escherichia coli (Escherichia coli), Bacillus subtilis, Bacillus megaterium, Bacillus amyloliquefaciens, Corynebacterium glutamicum, Saccharomyces cerevisiae, Candida utilis or Pichia pastoris; optionally, the host strain is selected from wild or genetically engineered Escherichia coli (Escherichia coli). Escherichia coli cells can be Escherichia coli strains derived from Escherichia coli K12 (such as MG1655, W3110, DH10b, DH1, BW2952 and strains derived therefrom) or any Escherichia coli strain of Escherichia coli B or strains derived therefrom.

[0045] A backbone plasmid capable of autonomous replication in a host cell can be any plasmid that can replicate in the host cell. In one embodiment, the expression plasmid vector contains a backbone plasmid that can replicate in Escherichia coli. Examples of backbone plasmids include, but are not limited to, backbone plasmids that can replicate in Escherichia coli strains, such as pUC (e.g., pUC18 and pUC19 plasmids), pBR322, pSC101, p15a, pACYC, pET, and pSC101 plasmids, and plasmids derived therefrom.

[0046] Another aspect of the present invention provides a method for preparing lysine or a derivative thereof, comprising culturing the above-mentioned transformant or mutant host cell in the presence of ethylene glycol to obtain lysine or a derivative thereof.

[0047] In one embodiment of the present invention, the above-mentioned engineered strain is fermentatively cultured in a medium containing ethylene glycol to obtain lysine or a derivative thereof.

[0048] In one embodiment of the present invention, ethylene glycol accounts for 0.01% - 20% (weight ratio) of the medium.

[0049] Another aspect of the present invention provides a method for increasing the expression level of lysine or a derivative thereof, the method comprising adding ethylene glycol to the medium, preferably, the cumulative addition amount of ethylene glycol is greater than 10 g / L, and / or introducing a first group of polynucleotides into the fermenting strain.

[0050] Another aspect of the present invention provides a chassis strain, which is an Escherichia coli strain, in which the expression of one or two of the following genes in the Escherichia coli strain is inhibited, attenuated, or eliminated: glyoxylate / hydroxypyruvate reductase ycdW or / and NADPH-dependent aldehyde reductase yqhD.

[0051] In a further preferred embodiment of the present invention, the generation pathways of metabolic by-products succinic acid, lactic acid, ethanol, acetic acid, and formic acid and the lysine degradation pathway in the chassis strain are inhibited or blocked.

[0052] In a further preferred embodiment of the present invention, the expression of one, two, or more of the following genes in the chassis strain is inhibited, attenuated, or eliminated: phosphoacetyltransferase pta, pyruvate oxidase poxB, alcohol dehydrogenase adhE, pyruvate-formate lyase pflB, acetolactate synthase mgsA, D-lactate dehydrogenase ldhA, fumarate reductase flavoprotein subunit frdA, lysine decarboxylase 1 cadA, and lysine decarboxylase 2 ldcC.

[0053] Beneficial technical effects

[0054] The present invention provides an expression vector, a transformant or a mutant host cell, and the transformant or mutant host cell utilizes ethylene glycol, thereby increasing the expression level of lysine. Detailed implementation manners

[0055] The synthesis method of the present invention will be further described in detail below in combination with specific embodiments. It should be understood that the following embodiments are only for illustrative explanation of the present invention and should not be construed as limiting the protection scope of the present invention. All technologies implemented based on the above content of the present invention are covered within the scope of protection intended by the present invention.

[0056] Materials and methods

[0057] LB medium: 10 g / L peptone, 5 g / L yeast extract, and 10 g / L sodium chloride.

[0058] Fermentation medium: 20 g / L glucose, 5 g / L yeast extract, 11.3 g / L M9 salts, 2 mM magnesium sulfate, 0.1 mM calcium chloride, 10 g / L ethylene glycol, 5 mg / L VB1, 5 g / L threonine, 10 g / L calcium carbonate. The pH of the medium was adjusted to 7.3 - 7.4 with concentrated ammonia water and sterilized at 115 °C for 15 min.

[0059] Flask fermentation method: Pick a single colony from the activated strain on an LB plate (containing an appropriate concentration of antibiotics) at 37 °C and inoculate it into an LB liquid medium (containing an appropriate concentration of antibiotics), and culture it at 37 °C for 12 - 16 h at a rotation speed of 220 rpm. Inoculate the LB overnight culture into a 250 mL flask containing 25 mL of fermentation medium (containing 10 g / L CaCO3 as a pH stabilizer) with appropriate concentrations of ampicillin, kanamycin, and streptomycin at an inoculation amount of 1%; after sealing with a breathable membrane, culture it at 30 °C and 220 rpm until the OD600 reaches 1, then add IPTG (final concentration 0.2 mM) to induce plasmid expression, and continue to culture for 36 h before stopping fermentation and sampling.

[0060] Determination of the concentrations of L-lysine, glucose, and ethylene glycol (EG): All standard products used were purchased from Sigma-Aldrich Corporation (www.sigmaaldrich.cn). Take 1 mL of the fermentation broth, centrifuge at 10,000 r / min for 5 min to remove the cells, and filter the obtained filtrate through a filter membrane with a pore size of 0.22 μm. After diluting the sample filtrate by an appropriate multiple, use high-performance liquid chromatography (HPLC) to determine the concentrations of the above products in the sample.

[0061] Determination conditions for glucose and ethylene glycol (EG): The high-performance liquid chromatograph is Shimadzu Nexera LC-40, and the chromatographic column is Bio-Rad Aminex HPX-87H 300×7.8 mm. The column oven is set at 40 °C; the detector is a refractive index detector (RID) (the detector is set at a constant temperature of 40 °C). The mobile phase is 5 mM sulfuric acid solution, and the flow rate is 0.6 mL / min.

[0062] Determination conditions for L-lysine: The high-performance liquid chromatograph is Shimadzu LC-40D; the chromatographic column is Welch UltimateAQ-C18, 4.6×250 mm; the column oven is set at 40 °C; the detector is an ultraviolet detector (the detector is set at a constant temperature of 40 °C), and the detection wavelength is 338 nm; the mobile phase is an aqueous sodium acetate solution and methanol, with gradient elution.

[0063] Information on the enzymes involved in the present invention is as follows:

[0064] Table 2 Enzyme information involved in the present invention

[0065]

[0066]

[0067] In the context of the present application, the enzymes mentioned include mutants that maintain enzyme activity, and the mutants have an amino acid sequence with at least 98% or at least 99% sequence identity to the amino acid sequence represented by the protein accession number in the table.

[0068] The biological materials constructed in the present invention are as follows in the table:

[0069] Table 3 Biological materials constructed in the present invention

[0070]

[0071] Examples

[0072] Example 1: Construction of an L-lysine synthesis chassis strain

[0073] Using the E. coli Keio Knockout Collection library 1Phages were prepared using single-gene knockout strains corresponding to (Horizon Discovery, CO, USA). The DNA fragment lacking the target gene with kanamycin (Kan) resistance was introduced into the starting strain Escherichia coli BW25113 using the P1 phage transfection method, and then spread on an LB plate containing 50 mg / L kanamycin and cultured overnight at 37 °C to obtain a deletion strain with Kan resistance. Then, plasmid pCP20 was transformed into the above-mentioned Kan-resistant transformant, spread on an LB plate containing 100 mg / L ampicillin, and cultured at 30 °C for 24 hours. The correct transformants with the kanamycin resistance gene Kan removed from the target gene were identified by PCR, thus obtaining a deletion strain without resistance. Then, the correct transformants with the Kan gene removed were streaked for single colonies on an LB plate and cultured at 37 or 42 °C, and finally, an Escherichia coli strain without resistance and without the pCP20 plasmid was obtained. By repeating this process, a deletion strain Lys00 (ldhA Δpta ΔpoxB ΔpflB ΔmgsA ΔfrdA ΔadhE ΔcadA ΔldcC) based on Escherichia coli K12 strain background BW25113 was constructed, in which the production pathways of metabolic by-products (succinic acid, lactic acid, ethanol, acetic acid, and formic acid) and the partial decomposition pathway of L-lysine were blocked and knocked out to avoid waste of carbon sources and reduce the decomposition of L-lysine.

[0074] Based on the Lys00 strain, strains Lys01 (Lys00 ΔyqhD), Lys02 (Lys00 ΔycdW), and Lys03 (Lys00 ΔyqhD ΔycdW) were obtained after combinatorial knockout of the yqhD and ycdW genes.

[0075] Example 2: Construction of recombinant plasmids pZE-ec.gldA, pZE-fucO, pZE-aldA, pZE-fucO-aldA, pZE-ec.gldA-aldA, pZE-kp.gldA-aldA, pZA-dapA H56K -ddh-lysA-dapB-ppc and pZS-aspC-lysC T352I -Construction of asd-ykuQ-patA-ykuR

[0076] The kp.gldA gene was cloned from the Klebsiella pneumoniae genome by PCR; the genes fucO, ec.gldA, and aldA were cloned from the Escherichia coli BW25113 genome, and the obtained DNA fragments were ligated and combined in different ways to the plasmid pZElac using Gibson Assembly 2 The above-obtained DNA fragments were ligated and combined in different ways to the plasmid pZElac 3After the lac promoter, the following recombinant plasmids were obtained (for details of the combination method, please refer to the Materials and Methods section): pZE-ec.gldA, pZE-aldA, pZE-fucO, pZE-ec.gldA-aldA, pZE-kp.gldA-aldA, and pZE-fucO-aldA.

[0077] The gene dapA in the genome of E. coli BW25113 was cloned by PCR H56K , ddh, lysA, dapB, and ppc. The dapA gene was cloned in two fragments, and the H56K mutation was introduced by primers near the fragment interface 4 . The obtained cloned fragments were ligated to the lac promoter of plasmid pZAlac using Gibson Assembly to obtain the recombinant plasmid pZA-dapA H56K -ddh-lysA-dapB-ppc (pLYS01).

[0078] The genes aspC, lysC T352I and asd in the genome of E. coli BW25113 and the genes ykuQ, patA, and ykuR in Bacillus subtilis 168 were cloned by PCR. The lysC gene was cloned in two fragments, and the T352I mutation was introduced by primers near the fragment interface 5 . The obtained cloned fragments were ligated to the lac promoter of plasmid pZAlac using Gibson Assembly to obtain the recombinant plasmid pZS-aspC-lysC T352I -asd-ykuQ-patA-ykuR (pLYS02).

[0079] The above recombinant plasmids were transformed into the Lys00-03 strain. For details of the specific plasmid and strain combinations, please refer to the Materials and Methods section.

[0080] Example 3: Flask fermentation of strains Lys04, Lys05, and Lys06

[0081] Using the Lys04 strain as a control, flask fermentation was carried out. The composition of the fermentation medium and the fermentation conditions are shown in the Materials and Methods section. After 36 hours of fermentation, the fermentation data are shown in Table 4. The results show that the overexpression of the first gene fucO or gldA in the ethylene glycol (EG) metabolic pathway increased the L-lysine production of Lys05 and Lys06 compared to the control strain (Lys04 without overexpression of genes related to the EG metabolic pathway).

[0082] Table 4: Flask fermentation data of L-lysine

[0083]

[0084] Example 4: Flask Fermentation of Strains Lys04, Lys07, Lys08 and Lys09

[0085] Using strain Lys04 as a control, flask fermentation was carried out. The composition of the fermentation medium and the fermentation conditions can be found in the Materials and Methods section. The fermentation data after 36 hours of fermentation are shown in Table 5. The results showed that the introduction of aldA on the basis of overexpression of gldA / fucO significantly increased the consumption of EG; at the same time, compared with the control strain, the L-lysine yield of the strain overexpressing gldA / fucO-aldA increased significantly, and the increase in L-lysine of the strain overexpressing ec.gldA (Lys09) was higher than that of the strain overexpressing fucO (Lys08). In addition, the single overexpression of the aldA gene (Lys07) could also slightly increase the consumption of ethylene glycol and the production of L-lysine.

[0086] Table 5: Flask Fermentation Data of L-Lysine

[0087]

[0088] Example 5: Effects of Deletion of yqhD and / or ycdW Genes on L-Lysine Fermentation

[0089] To explore the roles of the side reaction enzymes YqhD and YcdW in the EG utilization pathway, using strain Lys09 as a control, flask fermentation was carried out. The composition of the fermentation medium and the fermentation conditions can be found in the Materials and Methods section. The fermentation data after 36 hours of fermentation are shown in Table 6. The results showed that the knockout of the yqhD and / or ycdW genes had no obvious effect on the utilization of glucose, but the ethylene glycol utilization rate and L-lysine yield of the single knockout strain and the double knockout strain were increased to a certain extent compared with the control group. In summary, the knockout of the yqhD and ycdW genes improved the ability of the strain to utilize ethylene glycol to a certain extent and at the same time increased the yield of L-lysine.

[0090] Table 6: Flask Fermentation Data of L-Lysine

[0091]

[0092] Example 6: Effects of gldA from Other Sources on L-Lysine Fermentation

[0093] Using the Lys12 strain as a control, the strain Lys13 carrying the Klebsiella pneumoniae kp.gldA gene was co-fermented in a shake flask. The composition of the fermentation medium and the fermentation conditions can be found in the Materials and Methods section. After 36 hours of fermentation, the fermentation data are shown in Table 7. The Klebsiella pneumoniae kp.gldA gene has better activity, resulting in an increase in the L-lysine production of Lys13 compared to Lys12.

[0094] Table 7: Shake flask fermentation data of L-lysine

[0095]

[0096] References

[0097] 1. Baba, T.; Ara, T.; Hasegawa, M.; Takai, Y.; Okumura, Y.; Baba, M.; Datsenko, K. A.; Tomita, M.; Wanner, B. L.; Mori, H., Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Molecular Systems Biology 2006, 2(1), 2006.0008.

[0098] 2. Gibson, D. G.; Young, L.; Chuang, R.-Y.; Venter, J. C.; Hutchison, C. A.; Smith, H. O., Enzymatic assembly of DNA molecules up to several hundred kilobases. Nature Methods 2009, 6(5), 343 - 345.

[0099] 3. Zhang, K.; Li, H.; Cho, K. M.; Liao, J. C., Expanding metabolism for total biosynthesis of the nonnatural amino acid L-homoalanine. Proceedings of the National Academy of Sciences 2010, 107(14), 6234 - 6239.

[0100] 4. Xu, J.; Han, M.; Ren, X.; Zhang, W., Modification of aspartokinase III and dihydrodipicolinate synthetase increases the production of l-lysine in Escherichia coli. Biochemical Engineering Journal 2016, 114, 79-86.

[0101] 5. Ogawa-Miyata, Y.; Kojima, H.; Sano, K., Mutation Analysis of the Feedback Inhibition Site of Aspartokinase III of Escherichia coli K-12 and its Use in L-Threonine Production. Bioscience, Biotechnology, and Biochemistry 2001, 65(5), 1149-1154.

Claims

1. An expression plasmid vector or combination of expression plasmid vectors, said vector or combination comprising: a first group of polynucleotides and a second group of polynucleotides, said first group of polynucleotides comprising at least one polynucleotide encoding an enzyme that promotes the utilization of ethylene glycol; said second group of polynucleotides comprising at least one polynucleotide encoding an enzyme in the lysine synthesis pathway; and a backbone plasmid that can replicate autonomously in a host cell.

2. The expression plasmid vector or combination of expression plasmid vectors according to claim 1, said plasmid vector or combination of vectors being used to promote the utilization of ethylene glycol by a host cell and / or enhance the expression level of lysine.

3. The expression plasmid vector or combination of expression plasmid vectors according to claim 1, said first group of polynucleotides comprising a) a gene encoding glycerol dehydrogenase gldA or a mutant thereof, or lactaldehyde reductase fucO or a mutant thereof; and / or b) a gene encoding lactaldehyde dehydrogenase (aldA) or a mutant thereof.

4. The expression plasmid vector or combination of expression plasmid vectors according to claim 3, wherein the glycerol dehydrogenase is a glycerol dehydrogenase or a propanediol / glycerol bifunctional dehydrogenase derived from the genus Escherichia, such as AAC43051 derived from Escherichia coli, or a glycerol dehydrogenase derived from Escherichia albertii such as OSL28309.1; or a glycerol dehydrogenase derived from Klebsiella pneumoniae such as ABR79620, or a glycerol dehydrogenase derived from the genus Shigella such as Shigella boydii or Shigella dysenteriae (such as ABB68416.1 or ABB63725.1), or a glycerol dehydrogenase derived from Streptococcal pneumoniae such as VTQ29411.1, or a glycerol dehydrogenase derived from Bacillus stearothermophilus such as AAA22477, or a glycerol dehydrogenase (alcohol / choline dehydrogenase) derived from Bacillus subtilis such as CAB15083.2, or a glycerol dehydrogenase derived from Pseudomonas putida such as AAC44426, or a glycerol dehydrogenase derived from Clostridium saccharobutylicum such as AAA83520.1, or a glycerol dehydrogenase derived from Clostridium acetobutylicum such as AAK79593.1, or a glycerol dehydrogenase derived from the genus Salmonella such as CNU06578.1, or an alcohol dehydrogenase (glycerol dehydrogenase) derived from Corynebacterium glutamicum such as SJM54452.

1. It may also be a propanediol / glycerol bifunctional dehydrogenase MTU07760.1 derived from the genus Parasutterella excrementihominis, as well as natural or artificial mutants of enzymes derived from the same species. The glycerol dehydrogenase gldA is derived from Escherichia coli; or derived from Klebsiella pneumoniae. Preferably, the glycerol dehydrogenase gldA derived from Escherichia coli has a protein sequence accession number of AAC43051 (ec.gldA); preferably, the glycerol dehydrogenase gldA derived from Klebsiella pneumoniae has a protein sequence accession number of ABR79620 (kp.gldA); or an enzyme having at least 96% or 97% or 98%, or at least 99% sequence identity with the amino acid sequence represented by the protein accession number AAC43051 or ABR79620 while maintaining the above enzyme activity.

5. The expression plasmid vector or expression plasmid vector combination according to claim 3, wherein the lactaldehyde reductase fucO is derived from Escherichia coli. Preferably, the lactaldehyde reductase fucO has a protein sequence accession number of AAA23825, or an enzyme having at least 96% or 97% or 98%, or at least 99% sequence identity with the amino acid sequence represented by the protein accession number AAA23825 while maintaining the above enzyme activity. Preferably, it is the lactaldehyde reductase fucO mutant FucO I6L,L7V .

6. The expression plasmid vector or expression plasmid vector combination according to claim 1 or 2, wherein the second group of polynucleotides comprises at least one gene of at least one enzyme in the following lysine biosynthetic pathway: The lysine biosynthetic pathway of KEGG entry M00016; The lysine biosynthetic pathway of KEGG entry M00525; The lysine biosynthetic pathway of KEGG entry M00526; The lysine biosynthetic pathway of KEGG entry M00527; The lysine biosynthetic pathway of KEGG entry M00030; The lysine biosynthetic pathway of KEGG entry M00433; and The lysine biosynthetic pathway of KEGG entry M00031; Preferably, the second group of polynucleotides comprises one or more genes of the lysine biosynthetic pathway of KEGG entry M00016; Preferably, the second group of polynucleotides comprises one or more genes listed in Table 1 and further comprises a polynucleotide coding sequence of a homologous polypeptide involved in lysine biosynthesis and homologous to any of the enzymes listed in Table 1; Preferably, the second group of polynucleotides comprises one or more genes encoding the following enzymes: aspartate aminotransferase aspC, aspartate kinase lysC, aspartate semialdehyde dehydrogenase asd, 4-hydroxy-tetrahydrodipicolinate synthase dapA, meso-diaminopimelate dehydrogenase ddh, 4-hydroxytetrahydropyridinedicarboxylic acid reductase dapB, pimelate decarboxylase LysA, tetrahydropicolinate acetyltransferase ykuQ, N-acetyl-L,L-diaminopimelate aminotransferase patA or N-acetyl-diaminopimelate deacetylase ykuR.

7. The expression plasmid vector or combination of expression plasmid vectors according to claim 1 or 2, wherein the vector or combination of vectors further comprises a third group of polynucleotides, and the third group of polynucleotides comprises at least one polynucleotide encoding an enzyme that promotes OAA accumulation; preferably phosphoenolpyruvate carboxylase ppc [EC:4.1.1.31].

8. The expression plasmid vector or combination of expression plasmid vectors according to claim 1 or 2, wherein the vector or combination of vectors further comprises a fourth group of polynucleotides, and the fourth group of polynucleotides comprises at least one polynucleotide encoding a polypeptide that aids in lysine synthesis, such as a tetracycline efflux pump polypeptide or a fragment thereof.

9. The expression plasmid vector or combination of expression plasmid vectors according to claim 1 or 2, wherein the vector or combination of vectors further comprises a fifth group of polynucleotides, and the fifth group of polynucleotides comprises at least one polynucleotide encoding a lysine derivative synthase; furthermore, the lysine derivative is cadaverine, and the lysine derivative synthase is lysine decarboxylase.

10. The expression plasmid vector or combination of expression plasmid vectors according to claim 9, wherein the polynucleotides in the first to fifth groups of polynucleotides are homologous or heterologous to the host cell; and / or, the polynucleotides in the first to fifth groups of polynucleotides comprise codon optimization for the host cell; and / or, the polynucleotides in the first to fifth groups of polynucleotides are operably linked to a promoter, and the promoter is homologous or heterologous to the host cell.

11. A transformant comprising one or more of the expression plasmid vectors or combinations thereof according to any one of claims 1-10 in a host cell.

12. A mutant host cell comprising the first group of polynucleotides and the second group of polynucleotides integrated into the chromosome of the host cell; Preferably, the mutant host cell further comprises a third group of polynucleotides, a fourth group of polynucleotides or a fifth group of polynucleotides; The first to fifth groups of polynucleotides are as described in any one of claims 1-10.

13. The transformant according to claim 11 or the mutant host cell according to claim 12, wherein the expression of one or both of the following genes in the transformant or mutant host cell is inhibited, attenuated or eliminated: glyoxylate / hydroxypyruvate reductase ycdW and / or NADPH-dependent aldehyde reductase yqhD; In a further preferred embodiment of the present invention, the production pathways of metabolic by-products succinic acid, lactic acid, ethanol, acetic acid and formic acid and the lysine degradation pathway in the transformant or mutant are inhibited or blocked. In a specific embodiment of the present invention, the host strain of the transformant or mutant host cell is selected from bacteria or fungi; optionally, the host strain is selected from wild or genetically engineered Escherichia coli, Bacillus, Corynebacterium, yeast or Streptomyces; optionally, the host strain is selected from wild or genetically engineered Escherichia coli (Escherichia coli), Bacillus subtilis (Bacillus subtilis), Bacillus megaterium (Bacillus megaterium), Bacillus amyloliquefaciens (Bacillus amyloliquefaciens), Corynebacterium glutamicum (Corynebacterium glutamicum), Saccharomyces cerevisiae (Saccharomyces cerevisiae), Candida utilis (Candida utilis) or Pichia pastoris (Pichia pastoris); optionally, the host strain is selected from wild or genetically engineered Escherichia coli (Escherichia coli).

14. A method for preparing lysine or a derivative thereof, comprising culturing the transformant according to claim 11 or the mutant host cell according to claim 12 in the presence of ethylene glycol to obtain lysine or a derivative thereof; Preferably, the above transformant or mutant host cell is fermentatively cultured in a medium containing ethylene glycol to obtain lysine or a derivative thereof; Preferably, ethylene glycol accounts for 0.01%-20% (weight ratio) of the medium.

15. A method for increasing the expression level of lysine or a derivative thereof, the method comprising adding ethylene glycol to the medium, preferably, the cumulative addition amount of ethylene glycol is greater than 10 g / L, and / or introducing the first group of polynucleotides according to claim 1 into the fermentation strain.

16. A chassis strain, which is an Escherichia coli strain, wherein the expression of one or both of the following genes in the Escherichia coli strain is inhibited, attenuated or eliminated: glyoxylate / hydroxypyruvate reductase ycdW and / or NADPH-dependent aldehyde reductase yqhD; Preferably, the generation pathways of metabolic by-products succinic acid, lactic acid, ethanol, acetic acid and formic acid and the lysine degradation pathway in the chassis strain are inhibited or blocked; Preferably, the expression of one, two or more of the following genes in the chassis strain is inhibited, weakened or eliminated: phosphoacetyltransferase pta, pyruvate oxidase poxB, alcohol dehydrogenase adhE, pyruvate-formate lyase pflB, methylglyoxal synthase mgsA, D-lactate dehydrogenase ldhA, fumarate reductase flavoprotein subunit frdA, lysine decarboxylase 1 cadA and lysine decarboxylase 2 ldcC.

Citation Information

Patent Citations

  • Expression of recombinant tetracycline efflux pumps for production of lysine or lysine-derived products, and methods and applications thereof

    CN106795209A